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esponsibility of InstAbstract The expression of phase-I drug metabolizing enzymes in liver changes dramatically during
postnatal liver maturation. Farnesoid X receptor (FXR) is critical for bile acid and lipid homeostasis in liver.
However, the role of FXR in regulating ontogeny of phase-I drug metabolizing genes is not clear. Hence, we
applied RNA-sequencing to quantify the developmental expression of phase-I genes in both Fxr-null and
control (C57BL/6) mouse livers during development. Liver samples of male C57BL/6 and Fxr-null mice at
6 different ages from prenatal to adult were used. The Fxr-null showed an overall effect to diminish the “day-
1 surge” of phase-I gene expression, including cytochrome P450s at neonatal ages. Among the 185 phase-I
genes from 12 different families, 136 were expressed, and differential expression during development
occurred in genes from all 12 phase-I families, including hydrolysis: carboxylesterase (Ces), paraoxonase
(Pon), and epoxide hydrolase (Ephx); reduction: aldoketo reductase (Akr), quinone oxidoreductase (Nqo), and
dihydropyrimidine dehydrogenase (Dpyd); and oxidation: alcohol dehydrogenase (Adh), aldehyde dehydro-
genase (Aldh), ﬂavin monooxygenases (Fmo), molybdenum hydroxylase (Aox and Xdh), cytochrome P450
(P450), and cytochrome P450 oxidoreductase (Por). The data also suggested new phase-I genes potentially
targeted by FXR. These results revealed an important role of FXR in regulation of ontogeny of phase-I genes.
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Phase-I drug metabolizing enzymes catalyze the oxidation, reduc-
tion, and hydrolysis of xenobiotics. A functional transition occurs in
liver after birth, and most of the phase-I drug-metabolizing enzymes
mature during this period in mouse liver1,2. Changes in expression
of some phase-I enzymes during liver maturation in humans have
also been reported, including cytochrome P450 (P450s)3–6, carbox-
ylesterase (CES)7,8, paraoxonase (PON)9,10, alcohol dehydrogenase
(ADH)11, and ﬂavin monooxygenase (FMO)12–14. The dynamic
changes in the ontogenic expression of these genes are thought to be
responsible for the substantial pharmacokinetic differences between
newborns and adults, and this contributes to differences in
therapeutic efﬁcacy and adverse drug reactions in pediatric
patients15–19. An in-depth understanding of the regulatory mechan-
isms of the ontogeny of phase-I enzymes is needed for safer and
more effective drug therapy for pediatric patients.
Farnesoid X receptor (FXR) is a bile acid sensing nuclear receptor
in maintenance of bile acid homeostasis by feedback inhibition of
expression of important genes in bile acid synthesis, for example,
CYP7A1, which is the rate-limiting enzyme in the classic pathway of
bile acid synthesis, and CYP8B1, which is required for the synthesis
of cholic acid20. FXR also plays a role in liver regeneration21.
Dysfunction of FXR may lead to development of digestive system
diseases22 and alcoholic liver disease23. The role of FXR in regulating
certain drug metabolizing enzyme genes has also been established.
Bile acids activate FXR in the intestine and liver, which induces the
expression of PXR, facilitating the detoxiﬁcation of lithocholate and
xenobiotics by inducing CYP3A, phase-II enzymes (e.g., sulfotrans-
ferase 2A1), and transporters (e.g., MRP2 and MRP3) xenobio-
tics24,25. A functional FXR polymorphism is common (2.5%–12%),
and has been associated with changes in FXR-target gene expression
in humans26,27. Understanding the regulatory mechanism of FXR on
hepatic expression of drug metabolizing enzyme genes in newborns
will greatly help us to understand the natural and aberrant develop-
ment of drug metabolizing enzyme genes in pediatric pharmacology.
In the current study, we used RNA-sequencing to quantify
hepatic phase-I metabolizing enzyme gene expression during the
developmental period from perinatal stage to adult in both wild-type
and a well-established Fxr knockout mouse model20. FXR has
been conﬁrmed to be knocked out in whole body in this Fxr-null
model. Our results revealed the signiﬁcant differences in Fxr-null
livers compared to control livers during postnatal development, and
suggested novel roles of FXR in the regulation of phase-I gene
developmental expression.2. Materials and methods
2.1. Animals
We used C57BL/6 mice as the wild-type animals. The animal
purchase, breeding and tissue collection for wild-type mice were
performed as previously described1,2. An Fxr-deﬁcient mouse
model28 was used to examine the role of FXR in determination of
ontogeny of phase-I drug metabolizing enzyme genes in mouse
liver. These knockout mice were bred under standard conditions in
the Ofﬁce of Animal Care Facility at the University of Connecticut
(Storrs, CT, USA). The use of these mice was approved by the
University of Connecticut's Institutional Animal Care and Use
Committee. Liver samples (n¼3) from wild-type and Fxr–/– mice
were collected at the following 6 ages: day –2 (gestational day17.5), day 1 (exactly 24 h after birth), and days 5, 20, 25, and 60
(collected at approximately 9:00 AM). These ages represent the
periods of prenatal (day –2), neonatal (days 1 and 5), juvenile
(days 20 and 25), and young adult (day 60). Due to potential
variations caused by the estrous cycle in maturing female mice,
only male livers were used in this study. The livers were
immediately frozen in liquid nitrogen after removal and stored at
–80 1C.
2.2. Total RNA extraction, sequencing library construction, and
RNA-Seq
RNA extraction, library construction, RNA-Seq, and FASTQ data
ﬁle collection were performed as previously described2.
2.3. RNA-Seq data analysis
For comparison of phase-I genes between wild-type and Fxr-
knockout samples at the 6 ages of days –2, 1, 5, 20, 25 and 60, the
RNA-Seq reads from the FASTQ ﬁles of these two types of mice
were mapped to the mouse reference genome (GRCm38/mm10)
by Tophat 2.0.8. The output ﬁles in BAM format were analyzed by
Cufﬂinks 2.1.1 to estimate the transcript abundance.
2.4. Data visualization and statistics
In this study, we consider genes with FPKM41 as expressed.
ANOVA was used to test for signiﬁcant difference in expression
between wild-type and Fxr-null mice. P values were adjusted
using Benjamini-Hochberg algorithm with a threshold of 0.05. To
study the distance of phase-I gene ontogenic pattern between WT
and Fxr–/– samples, the average FPKM values from three
individual animals were used. For each gene, the FPKM values
at the 12 ages (6 ages per genotype) were divided by the mean
FPKM of the 12 ages before calculating distance in order to
normalize the difference of expression level among genes.3. Results
3.1. Phase-I gene ontogeny in Fxr–/– mice
For all the P450 genes, signiﬁcant differences in total mRNA
expression between wild-type and Fxr–/– mice were found at ages
of days –2, 1 and 5 (Fig. 1A). The expression of total P450s was
higher before birth and lower after birth till day 5 in Fxr–/– mice
than in wild-type. There was a surge in expression of P450 genes
around birth. From days –2 to day 1, the total P450 mRNA level
increased more than 12-fold in wild-type mice, yet this increase
was less than 5-fold in Fxr–/– mice (Fig. 1A). The total P450
mRNAs reached similar levels from days 20 to 60 in both wild-
type and Fxr-null mice. A similar change in total mRNA
expression of non-P450 phase I genes between wild-type and
Fxr–/– mice was found in Fig. 1B.
When examining the composition of different families of phase-
I genes within this total expression, we also found dramatic
changes around birth and signiﬁcant differences between wild-type
and Fxr-null mice (Fig. 2). At day –2, the mRNA percentage of
Akr and Aldh were much lower and the percentage of Adh and Ces
were much higher in Fxr-null mice compared with wild-type mice.
The percentage of P450 mRNAs in all phase-I genes nearly
Figure 1 Total mRNA levels of the 102 P450 genes (A) and 185 non-P450 phase-I genes (B) in the mouse liver during development. RNA-Seq
was done for liver mRNAs of wild-type C57BL/6 and Fxr-null male mice at 6 ages from 2 days before birth to 60 days after birth. The FPKM
values of all genes in the group at each age were added and plotted to show the developmental pattern of total mRNAs. Bars represent the mean
FPKM and SEM of three individual animals. Star sign indicates signiﬁcant difference of expression between wild-type and Fxr-null mice with
adjusted Po0.05.
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percentage was much lower in Fxr-null mice at days 1 and 5. Ces
was a family of phase-I genes that showed dramatically higher
percentage of expression in Fxr-null mice at perinatal stage of days
–2, 1 and 5 (Fig. 2). It is possible that the loss of FXR activated
other nuclear receptors or transcription factors in compensation
that induced Ces and Aldh expression at neonatal ages. When the
age got older, for example at days 25 and 60, both the total mRNA
and the composition of different families of phase-I gene expres-
sion became similar in wild-type and Fxr-null mice.
After examining the overall effect of Fxr knockout on phase-I
gene expression during liver development, we took a further step
to assess the ontogeny of individual phase-I genes. Based on
UCSC Genes Track mm10, there were 185 phase-I genes in the 12
major families of phase-I genes, and our data showed 136 of them
were expressed during liver maturation in wild-type (WT) and
Fxr–/– mice (average FPKM41). Differential expression between
wild-type and knockout mice occurred in genes from all 12 phase-I
gene families for at least one age during development, suggesting
an extensive role of FXR in gene regulation. The distances of
developmental pattern between WT and Fxr–/– samples were
calculated and phase-I genes were listed in the order from large
to small distance in Fig. 3. The genes at the upper part showedmore difference in their developmental expression patterns caused
by the knockout of Fxr, and the top 10 most altered genes were
Cyp26a1, Cyp4a12b, Cyp1a1, Adh6-ps1, Cyp2a4, Cyp7a1,
Cyp2d13, Fmo2, Cyp2d37-ps, and Akr1b7. Changes in expression
of these genes showed developmental stage-speciﬁc effects, for
example, Cyp26a1 and Cyp4a12b were only strongly induced or
repressed at day 60, Cyp2a4 was induced at adolescent stage, and
Akr1b7 was markedly repressed at neonatal stage in the knockout
mice compared with wild-type. Cyp3a11 is one of the most
important genes in drug metabolism. Research has shown that
CYP3A11 expression was induced in the absence of FXR29. But in
our results, induction of Cyp3a11 mRNA only happened at day 20
after birth, and Fxr–/– does not signiﬁcantly alter CYP3A11
ontogenic trend (Fig. 4).3.2. Developmental expression of known FXR target phase-I
genes
As we have found out widespread changes of gene expression in
Fxr-null mice, especially in those hepatic nuclear receptors and
core transcription factors, it would be difﬁcult for us to conclude
on the direct role of FXR in regulation of gene transcription.
Figure 2 Percentages of FPKM values of each phase-I family at ages
of days –2, 1, 5, 25, and 60 in both wild-type and Fxr-null mice. WT,
wild-type and KO, Fxr-null.
Figure 3 Developmental expression patterns of phase-I genes in
livers of wild-type and Fxr–/– mice. Heat map of expression proﬁles
are drawn for all expressed phase-I genes (FPKM41). The genes are
listed in an order based on the distance of ontogenic pattern between
WT and Fxr–/– samples, with the ones at the top showing patterns most
altered in Fxr-knockout mice.
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several known FXR target genes. CYP7A1 is the rate-limiting
enzyme in the classic bile acid synthesis pathway, and CYP8B1 is
required for synthesis of cholic acid. The known mechanisms of
FXR in regulating CYP7A1 and CYP8B1 are as follows. The
activation of FXR by bile acids in the liver induces nuclear
receptor SHP (Nr0b2), which interacts with HNF4α and LRH-1
and blocks their activation of Cyp7a1 and Cyp8b1 transcription.
Figure 4 Expression patterns of CYP3A11 during liver develop-
ment. Data are expressed as mean FPKM and SEM of three individual
animals.
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intestinal FGF-15 (FGF-19 in human), which circulates to liver
and bind FGFR4 to activate JNK phosphorylation pathway and
suppress Cyp7a1 and Cyp8b1 expression30. Our results demon-
strated that Cyp7a1 mRNA level was signiﬁcantly induced at allFigure 6 Expression patterns of (A) Pon1, (B) Pon2, and (C) Pon3 durin
three individual animals.
Figure 5 Expression patterns of (A) Cyp7a1, (B) Cyp8b1 and (C) Shp dur
three individual animals.6 ages in Fxr knockout mice, and the induction fold change was
largest at day 20, indicating the repression of CYP7A1 by FXR
was more critical at day 20 (Fig. 5A). Although it was proposed
that CYP7A1 and CYP8B1 were under the same FXR regulatory
pathway, Cyp8b1 mRNA level was not signiﬁcantly altered in Fxr-
null mice (Fig. 5B). So the regulation of FXR on Cyp8b1 gene was
relatively weak, and there might be other critical regulatory factors
that maintain the expression of CYP8B1 in the absence of FXR.
The expression of SHP, the direct target gene of FXR in the liver
pathway for regulation of CYP7A1 and CYP8B1, was only
reduced at young ages in Fxr-null mice, also suggesting develop-
mental stage-speciﬁc effect of FXR (Fig. 5C). And the result
indicated that the induction of CYP7A1 at day 60 was mainly due
to failed suppression from the FXR intestinal pathway. Taken
together, these data provided new insights for the role of FXR in
regulation of its target gene expression.3.3. Phase-I genes potentially targeted by FXR
Our data also suggested new phase-I genes potentially targeted by
FXR. Previous study has shown that bile acid and FGF19
treatment decreased PON1 mRNA level31. And in our Fxr-null
mice, the Pon1 mRNA level was induced during development
(Fig. 6A), which further supported the role of FXR in repression of
PON1 expression, probably through intestinal FXR function. Ing liver development. Data are expressed as mean FPKM and SEM of
ing liver development. Data are expressed as mean FPKM and SEM of
Figure 7 Expression patterns of (A) Aldh5a1, (B) Aldh6a1, and (C) Dpyd during liver development. Data are expressed as mean FPKM and
SEM of three individual animals.
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was also observed (Fig. 6B and C). Pon1/2/3 genes are located
next to each other in the genome and it is highly likely that they
are co-regulated by FXR.
Besides Cyp7a1, only three other genes, Aldh5a1, Aldh6a1 and
Dpyd, showed signiﬁcant changes of expression at all 6 ages in
Fxr-null mice (Fig. 7). ChIP-Seq study identiﬁed FXR binding on
Aldh5a1 gene32. So the mRNA basal expression of these phase-I
genes during development may be repressed by FXR. However,
further study is needed to validate the direct involvement of FXR
in control of the expression of these genes.4. Discussion
In this study, comparison of ontogeny of hepatic phase-I genes in
wild-type and Fxr-knockout mice by RNA-Seq revealed important
roles of FXR in regulating developmental expression of phase-I
genes. The loss of FXR resulted in signiﬁcant changes of phase-I
gene expression from all 12 major families, and suggested new
phase-I genes potentially targeted by FXR.
The baby mice take milk from their mother, which has a high
fat content. Bile acids are necessary for the absorption of fat, and
they are mainly synthesized and secreted at the immediate
perinatal period to facilitate milk absorption. As the endogenous
ligands for FXR, bile acids activated FXR signaling may be
important for regulating perinatal gene expression in liver. Studies
have shown that FXR functions to initiate the expression of major
bile acid transporters in newborn mice33. FXR is critical for the
“day 1 surge” pattern of Ntcp, Bsep, and Mdr2 in newborn mouse
liver. And here in our results, FXR is also critical for the “day
1 surge” of total phase-I expression (Fig. 1). The total mRNA of
P450s was expressed signiﬁcantly lower at newborn ages (days
1 and 5) in Fxr-null mice.
For the phase-I gene expressions most altered by the loss of
FXR, Cyp26a1 mRNA was highly induce at day 60. CYP26A1
functions in the catabolism of retinoic acid, and is normally
induced by increased retinol or retinoic acid levels. It is possible
that this gene induction is a result of altered metabolism in retinoic
acid pathway. The second gene in the distance list, Cyp4a12, was
markedly suppressed at day 60 (Fig. 3). Cyp4 gene family is
known to be regulated by PPAR receptors, and FXR can inﬂuence
PPAR expressions34. So this may also be an indirect effect of Fxr
knockout. Many genes identiﬁed in this project may be indirectly
regulated by FXR. With a complicated regulatory network, it isdifﬁcult for us to conclude on the role of FXR in some of the
changes of expression patterns. ChIP-Seq technology using
speciﬁc anti-FXR antibody is a powerful tool to identify
genome-wide FXR binding sites35. Future studies combining the
current data with ChIP-Seq experiments during liver development
would provide important information to understand the regulatory
mechanism of FXR on ontogeny of phase-I genes.
Quantifying the developmental expression is an initial step to
study ontogeny of phase-I genes. It utilized advanced technology
to generate an overall picture of gene expression, and revealed
potential ﬁelds of interest that await further researches. For
example, future studies to over-express FXR or treat the animals
with FXR agonists during development may complement the loss-
of-function study and help differentiate the direct and indirect
effects of FXR in regulating development gene expression.
Characterization of functional FXR polymorphisms in human
and their roles in bile acid homeostasis will help to understand
the important roles of FXR. Altogether, these studies would enable
a more profound understanding of liver development and ontogeny
of phase-I genes, and provide a foundation to assist researchers in
understanding developmental susceptibility and improving the
safety and effectiveness of pharmacotherapy in children.
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